Hiroshi Ikeuchi

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.

Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.

Journal: Cancer science

Published: March 19, 2025

Correction: GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.

Correction: GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.

Journal: Oncogene

Published: September 13, 2024

GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.

GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway.

Journal: Oncogene

Published: January 14, 2024

A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency.

A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency.

Journal: NPJ precision oncology

Published: November 27, 2023

The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.

The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.

Journal: Journal of neuro-oncology

Published: November 17, 2023

Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.

Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.

Journal: Clinical orthopaedics and related research

Published: March 28, 2023

High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.

High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.

Journal: Molecular cancer therapeutics

Published: April 29, 2022

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.

Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.

Journal: Oncogene

Published: November 24, 2021

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer.

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer.

Journal: NPJ precision oncology

Published: September 05, 2020

Showing 1-9 of 9

Last Updated: 09/26/2026